# Market Thesis Research Bundle

Question: Given the 2026 biotech deal surge and looming patent cliffs, will large-cap pharma keep using outright acquisitions as the main way to refill pipelines, as shown by another wave of billion-dollar biotech takeouts by year-end 2026?

What this bundle is: a reasoning and monitoring scaffold. It organizes public evidence into observations, claims, uncertainty branches, thresholds, and a watch plan.

What this bundle is not: primary evidence, live market data, trade advice, or a substitute for official, live, or current web sources.

Core tension: Given the 2026 biotech deal surge and looming patent cliffs, will large-cap pharma keep using outright acquisitions as the main way to refill pipelines, as shown by another wave of billion-dollar biotech takeouts by year-end 2026?

Current inference to verify: {'stance': 'mixed', 'summary': 'As of the cutoff, the evidence supports continued heavy large-cap pharma M&A into late 2026, but it does not yet establish that outright acquisitions will remain the single dominant pipeline-refill mechanism through year-end. The deal tape and patent-cliff disclosures both point toward persistent acquisition pressure, while several issuer disclosures show a broader mix of in-licensing, partnerships, and internal R&D that keeps the thesis unresolved.', 'confidence': 'medium', 'not_prediction_signal': True} Treat this as a hypothesis that must be refreshed against live official sources, not as a signal.

How to use: read `source_priority.json` first, refresh sources in `live_verification_plan.json`, then use `fact_inference_split.json`, `thresholds.json`, and `watch_schedule.json` to decide what changed. Do not infer buy/sell/hold, position sizing, execution, or asset-price direction from this artifact.